Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Generate Biomedicines, Inc. (GENB) had Income from Continuous Operations of $-222.97M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$31.89M |
|
$-249.52M |
|
-- |
|
$31.89M |
|
$266.96M |
|
$-235.06M |
|
$12.26M |
|
$-222.80M |
|
$-222.80M |
|
$-222.97M |
|
|
Income from Continuous Operations |
$-222.97M |
$-222.97M |
|
$-222.97M |
|
$-235.06M |
|
$-224.67M |
|
32.98M |
|
32.98M |
|
$-7.57 |
|
$-7.57 |
|
| Balance Sheet Financials | |
$234.37M |
|
$29.15M |
|
$95.82M |
|
$330.18M |
|
$82.20M |
|
$2.91M |
|
$863.94M |
|
$946.15M |
|
$-615.97M |
|
$-615.97M |
|
$-615.97M |
|
33.12M |
|
| Cash Flow Statement Financials | |
$-200.62M |
|
$116.77M |
|
$28.06M |
|
$181.83M |
|
$126.04M |
|
$-55.79M |
|
$20.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.85 |
|
-- |
|
-- |
|
-0.00 |
|
-0.01 |
|
100.00% |
|
-737.04% |
|
-737.04% |
|
-704.45% |
|
-698.59% |
|
-782.38% |
|
$-204.13M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
-- |
|
-- |
|
36.20% |
|
36.20% |
|
-67.53% |
|
36.37% |
|
$-18.60 |
|
$-6.19 |
|
$-6.08 |
|